2014-04-29 14:31:22 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Tibet Cheezheng Tibetan Med Co Ltd (2287) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Tibet Cheezheng Tibetan Med Co Ltd (2287). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Tibet Cheezheng Tibetan Med Co Ltd investor.
Report Summary: Tibet Cheezheng Tibetan Med Co Ltd is a high quality company with a positive outlook. Tibet Cheezheng Tibetan Med Co Ltd has strong business growth and is run by efficient management. The trend in Tibet Cheezheng Tibetan Med Co Ltd fair value exchange rate against its closest rated-competitor, Zhejiang Jingxin Pharmaceutical Co., Ltd, has been depreciating over the past 2 weeks. When compared to its closest competitor, Tibet Cheezheng Tibetan Med Co Ltd
shows similar undervaluation and is equally likely to outperform the market.
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Tibet Cheezheng Tibetan Med Co Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.